Biotherapeutics in Orthopaedic Medicine: Accelerating the Healing Process?

BioDrugs

Volumn 17, Issue 5, 2003, Pages 301-314

  Puleo, David A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; LIM MINERALISATION PROTEIN 1; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT DNA; RECOMBINANT OSTEOGENIC PROTEIN 1; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

BIODEGRADABILITY; BIOTECHNOLOGY; BONE ALLOGRAFT; BONE DEFECT; BONE DEVELOPMENT; BONE MARROW CELL; BONE MATRIX; BONE REGENERATION; BONE REMODELING; CALLUS; CELL DIFFERENTIATION; CELL TYPE; CLINICAL TRIAL; CONNECTIVE TISSUE; DNA MODIFICATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC CODE; HEALTH CARE COST; HUMAN; IMPLANT; IMPLANTATION; MESENCHYME CELL; MOLECULAR CLONING; MORBIDITY; MUSCULOSKELETAL INJURY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ORTHOPEDICS; OSTEOBLAST; OSTEOTOMY; PERIODONTAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINE FUSION; STEM CELL; SURGICAL TECHNIQUE; TIBIA FRACTURE; VIRAL GENE DELIVERY SYSTEM;

BIOTECHNOLOGY; HEALTH CARE COSTS; HUMANS; MUSCULOSKELETAL DISEASES; ORTHOPEDIC PROCEDURES; ORTHOPEDICS; WOUND HEALING;

EID: 0142091249     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317050-00001     Document Type: Review

References (126)

1. Praemer A, Furner S, Rice DP. Musculoskeletal conditions in the United States. Rosemont (IL): American Academy of Orthopaedic Surgeons. 1999
2. Einhorn TA. Enhancement of fracture-healing. J Bone Joint Surg Am 1995 Jun; 77 (6): 940-56
3. Lind M. Growth factors: possible new clinical tools. A review. Acta Orthop Scand 1996 Aug; 67 (4): 407-17
4. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop 1991 Feb; 263: 30-48
5. Lind M. Growth factor stimulation of bone healing: effects on osteoblasts, osteomies, and implants fixation. Acta Orthop Scand Suppl 1998 Oct; 283: 2-37
6. Iwata H, Sakano S, Itoh T, et al. Demineralized bone matrix and native bone morphogenetic protein in orthopaedic surgery. Clin Orthop 2002 Feb; 395: 99-109
7. Li H, Pujic Z, Xiao Y, et al. Identification of bone morphogenetic proteins 2 and 4 in commercial demineralized freeze-dried bone allograft preparations: pilot study. Clin Implant Dent Relat Res 2000; 2 (2): 110-7
8. Takikawa S, Bauer TW, Kambic H, et al. Comparative evaluation of the osteoinductivity of two formulations of human demineralized bone matrix. J Biomed Mater Res 2003 Apr 1; 65A (1): 37-42
9. Lucas PA, Syftestad GT, Goldberg VM. et al. Ectopic induction of cartilage and bone by water-soluble proteins from bovine bone using a collagenous delivery vehicle. J Biomed Mater Res 1989 Apr; 23 (A1 Suppl.): 23-39
10. Nielsen HM, Andreassen TT, Ledet T, et al. Local injection of TGF-beta increases the strength of tibial fractures in the rat. Acta Orthop Scand 1994 Feb; 65 (1): 37-41
11. Kato T, Kawaguchi H. Hanada K, et al. Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. J Orthop Res 1998 Nov; 16 (6): 654-9
12. Giannobile WV, Finkelman RD, Lynch SE. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: results following a single administration of PDGF/IGF-I. J Periodontol 1994 Dec; 65 (12): 1158-68
13. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002 Dec; 84-A (12): 2123-34
14. Ma Q, Mao T, Liu B, et al. Vascular osteomuscular autograft prefabrication using coral, type I collagen and recombinant human bone morphogenetic protein-2. Br J Oral Maxillofac Surg 2000 Oct; 38 (5): 561-4
15. Peter SJ, Lu L. Kim DJ, et al. Effects of transforming growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates. J Biomed Mater Res 2000 Jun; 50 (3): 452-62
16. Urist MR. Bone: formation by autoinduction. Science 1965 Nov 12; 150 (698): 893-9
17. Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res 1971 Nov-Dec; 50 (6): 1392-406
18. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998 Jan; 346: 26-37
19. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002 Dec; 23 (6): 787-823
20. Bostrom MP, Lane JM, Berberian WS, et al. Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J Orthop Res 1995 May; 13 (3): 357-67
21. Yu Y, Yang JL, Chapman-Sheath PJ, et al. TGF-beta, BMPs, and their signal transducing mediators, Smads, in rat fracture healing. J Biomed Mater Res 2002 Jun; 60 (3): 392-7
22. Wang EA, Rosen V, Cordes P, et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A 1988 Dec; 85 (24): 9484-8
23. Wang EA, Rosen V, D'Alessandro JS. et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990 Mar; 87 (6): 2220-4
24. Khan SN, Sandhu HS, Lane JM, et al. Bone morphogenetic proteins: relevance in spine surgery. Orthop Clin North Am 2002 Apr; 33 (2): 447-63
25. Bouxsein ML, Turek TJ, Blake CA, et al. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 2001 Aug; 83-A (8): 1219-30
26. Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 2000 Mar; 18 (2): 289-302
27. Gerhart TN, Kirker-Head CA, Kriz MJ. et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop 1993 Aug; 293: 317-26
28. Kusumoto K. Bessho K, Fujimura K, et al. Osteoinduction by recombinant human bone morphogenetic protein-2 in muscles of non-human primates. J Int Med Res 2002 May-Jun; 30 (3): 251-9
29. Sampath TK, Maliakal JC, Hauschka PV, et al. Recombinant human osteogenic protein-I (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992 Oct; 267 (28): 20352-62
30. Cook SD, Baffes GC, Wolfe MW, et al. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am 1994 Jun; 76 (6): 827-38
31. Cook SD, Baffes GC, Wolfe MW, et al. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop 1994 Apr; 301: 302-12
32. Cook SD, Wolfe MW, Salkeld SL, et al. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am 1995 May; 77 (5): 734-50
33. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001; 83-A Suppl. 1 (Pt 2): S151-8
34. Jeppsson C, Bostrom M, Aspenberg P. Intraosseous BMP implants in rabbits: inhibitory effect on bone formation. Acta Orthop Scand 1999 Feb; 70 (1): 77-83
35. Kujala S, Raatikainen T, Ryhanen J, et al. Composite implant of native bovine bone morphogenetic protein (BMP) and biocoral in the treatment of scaphoid nonunions: a preliminary study. Scand J Surg 2002; 91 (2): 186-90
36. Wurzler KK, DeWeese TL, Sebald W, et al. Radiation-induced impairment of bone healing can be overcome by recombinant human bone morphogenetic protein-2. J Craniofac Surg 1998 Mar; 9 (2): 131-7
37. Luppen CA, Blake CA, Ammirati KM, et al. Recombinant human bone morphogenetic protein-2 enhances osteotomy healing in glucocorticoid-treated rabbits. J Bone Miner Res 2002 Feb; 17 (2): 301-10
38. Chen X, Kidder LS, Lew WD. Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur. J Orthop Res 2002 Jan; 20 (1): 142-50
39. Solheim E. Growth factors in bone. Int Orthop 1998; 22 (6): 410-6
40. Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. Clin Orthop 1990 Jan; 250: 261-76
41. Joyce ME, Jingushi S, Bolander ME. Transforming growth factor-beta in the regulation of fracture repair. Orthop Clin North Am 1990 Jan; 21 (1): 199-209
42. Bourque WT, Gross M, Hall BK. Expression of four growth factors during fracture repair. Int J Dev Biol 1993 Dec; 37 (4): 573-9
43. Kasperk CH, Wergedal JE, Mohan S, et al. Interactions of growth factors present in bone matrix with bone cells: effects on DNA synthesis and alkaline phosphatase. Growth Factors 1990; 3 (2): 147-58
44. Noda M, Rodan GA. Type-beta transforming growth factor inhibits proliferation and expression of alkaline phosphatase in murine osteoblast-like cells. Biochem Biophys Res Commun 1986 Oct 15; 140 (1): 56-65
45. Iba K, Sawada N, Nuka S, et al. Phase-dependent effects of transforming growth factor beta 1 on osteoblastic markers of human osteoblastic cell line sV-HFO during mineralization. Bone 1996 Oct; 19 (4): 363-9
46. Zellin G, Beck S, Hardwick R, et al. Opposite effects of recombinant human transforming growth factor-betal on bone regeneration in vivo: effects of exclusion of periosteal cells by microporous membrane. Bone 1998 Jun; 22 (6): 613-20
47. Beck LS, Deguzman L, Lee WP, et al. TGF-beta 1 induces bone closure of skull defects. J Bone Miner Res 1991 Nov; 6 (11): 1257-65
48. Sumner DR, Turner TM, Purchio AF, et al. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am 1995 Aug; 77 (8): 1135-47
49. Lind M, Overgaard S, Nguyen T, et al. Transforming growth factor-beta stimulates bone ongrowth: hydroxyapatite-coated implants studied in dogs. Acta Orthop Scand 1996 Dec; 67 (6): 611-6
50. 2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury. J Orthop Res 2001 Jan; 19 (1): 85-94
51. Ripamonti U, Duneas N, Van Den Heever B, et al. Recombinant transforming growth factor-beta1 induces endochondral bone in the baboon and synergizes with recombinant osteogenic protein-1 (bone morphogenetic protein-7) to initiate rapid bone formation. J Bone Miner Res 1997 Oct; 12 (10): 1584-95
52. Lind M, Schumacker B. Soballe K, et al. Transforming growth factor-beta enhances fracture healing in rabbit tibiae. Acta Orthop Scand 1993 Oct; 64 (5): 553-6
53. Critchlow MA, Bland YS. Ashhurst DE. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995 May; 16 (5): 521-7
54. Heckman JD, Ehler W, Brooks BP, et al. Bone morphogenetic protein but not transforming growth factor-beta enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer. J Bone Joint Surg Am 1999 Dec; 81 (12): 1717-29
55. Finkelman RD, Mohan S, Jennings JC. et al. Quantitation of growth factors IGF-I, SGF/IGF-II, and TGF-beta in human dentin. J Bone Miner Res 1990 Jul; 5 (7): 717-23
56. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002 Oct; 175 (1): 19-31
57. Andrew JG, Hoyland J, Freemont AJ, et al. Insulin-like growth factor gene expression in human fracture callus. Calcif Tissue Int 1993 Aug; 53 (2): 97-102
58. Scheven BA, Hamilton NJ, Fakkeldij TM, et al. Effects of recombinant human insulin-like growth factor I and II (IGF-I/-II) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regul 1991 Dec; 1 (4): 160-7
59. Pfeilschifter J, Oechsner M, Naumann A, et al. Stimulation of bone matrix apposition in vitro by local growth factors: a comparison between insulin-like growth factor I, platelet-derived growth factor, and transforming growth factor beta. Endocrinology 1990 Jul; 127 (1); 69-75
60. McCarthy TL, Centrella M, Canalis E. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 1989 Jan; 124 (1): 301-9
61. Spencer EM, Liu CC, Si EC. et al. In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 1991; 12 (1): 21-6
62. Aspenberg P, Albrektsson T, Thorngren KG. Local application of growth-factor IGF-I to healing bone: experiments with a titanium chamber in rabbits. Acta Orthop Scand 1989 Oct; 60 (5): 607-10
63. Thaller SR, Lee TJ, Armstrong M, et al. Effect of insulin-like growth factor type 1 on critical-size defects in diabetic rats. J Craniofac Surg 1995 May; 6 (3): 218-23
64. Thaller SR, Salzhauer MA, Rubinstein AJ, et al. Effect of insulin-like growth factor type I on critical size calvarial bone defects in irradiated rats. J Craniofac Surg 1998 Mar; 9 (2): 138-41
65. Zhang L, Leeman E, Carnes DC, et al. Human osteoblasts synthesize and respond to platelet-derived growth factor. Am J Physiol 1991 Aug; 261: C348-54
66. Centrella M, McCarthy TL, Kusmik WF, et al. Relative binding and biochemical effects of heterodimeric and homodimeric isoforms of platelet-derived growth factor in osteoblast-enriched cultures from fetal rat bone. J Cell Physiol 1991 Jun; 147 (3): 420-6
67. Andrew JG, Hoyland JA, Freemont AJ, et al. Platelet-derived growth factor expression in normally healing human fractures. Bone 1995 Apr; 16 (4): 455-60
68. Hughes FJ, Aubin JE, Heersche JN. Differential chemotactic responses of different populations of fetal rat calvaria cells to platelet-derived growth factor and transforming growth factor beta. Bone Miner 1992 Oct; 19 (1): 63-74
69. Canalis E, Varghese S. McCarthy TL, et al. Role of platelet derived growth factor in bone cell function. Growth Regul 1992 Dec; 2 (4): 151-5
70. Canalis E, McCarthy TL, Centrella M. Effects of platelet-derived growth factor on bone formation in vitro. J Cell Physiol 1989 Sep; 140 (3): 530-7
71. Zhang Z, Chen J, Jin D. Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the roie of receptor beta. Biochem Biophys Res Commun 1998 Oct 9; 251 (1): 190-4
72. Nash TJ, Howlett CR, Martin C. et al. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 1994 Mar-Apr; 15 (2): 203-8
73. Vikjaer D, Blom S, Hjorting-Hansen E, et al. Effect of platelet-derived growth factor-BB on bone formation in calvarial defects; an experimental study in rabbits. Eur J Oral Sci 1997 Feb; 105 (1): 59-66
74. Arm DM, Tencer AF, Bain SD. et al. Effect of controlled release of platelet-derived growth factor from a porous hydroxyapatite implant on bone ingrowth. Biomaterials 1996 Apr; 17 (7): 703-9
75. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000 Feb; 22 (2): 108-12
76. McCarthy TL, Centrella M, Canalis E. Effects of fibroblast growth factors on deoxyribonucleic acid and collagen synthesis in rat parietal bone cells. Endocrinology 1989 Oct; 125 (4): 2118-26
77. Nakamura T, Hara Y, Tagawa M, et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 1998 Jun; 13 (6): 942-9
78. Radomsky ML, Aufdemorte TB, Swain LD, et al. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J Orthop Res 1999 Jul; 17 (4): 607-14
79. Kawaguchi H, Nakamura K, Tabata Y, et al. Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. J Clin Endocrinol Metab 2001 Feb; 86 (2): 875-80
80. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999 Jun; 14 (6): 960-8
81. Holzer G, Majeska RJ, Lundy MW, et al. Parathyroid hormone enhances fracture healing: a preliminary report. Clin Orthop 1999 Sep; 366: 258-63
82. Andreassen TT, Fledelius C, Ejersted C, et al. Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 2001 Jun; 72 (3): 304-7
83. Jahng JS, Kim HW. Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics 2000 Oct; 23 (10): 1089-94
84. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002 Nov 11; 162 (20): 2297-309
85. Howell TH, Fiorellini JP, Paquette DW, et al. A phase 1/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-1 in patients with periodontal disease. J Periodontol 1997 Dec; 68 (12): 1186-93
86. Takita H, Tsuruga E, Ono I, et al. Enhancement by bFGF of osteogenesis induced by rhBMP-2 in rats. Eur J Oral Sci 1997 Dec; 105 (6): 588-92
87. Schmidmaier G, Wildemann B, Bail H, et al. Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-beta1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone 2001 Apr; 28 (4): 341-50
88. Raschke M, Wildemann B, Inden P, et al. Insulin-like growth factor-1 and transforming growth factor-betal accelerates osteotomy healing using polylactide-coated implants as a delivery system: a biomechanical and histological study in minipigs. Bone 2002 Jan; 30 (1): 144-51
89. Blumenfeld I, Srouji S, Lanir Y, et al. Enhancement of bone defect healing in old rats by TGF-beta and IGF-1. Exp Gerontol 2002 Apr; 37 (4): 553-65
90. Marden LJ, Fan RS, Pierce GF, et al. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest 1993 Dec; 92 (6): 2897-905
91. Agha-Mohammadi S, Lotze MT. Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest 2000 May; 105 (9): 1177-83
92. Musgrave DS, Bosch P, Ghivizzani S, et al. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone 1999 Jun; 24 (6): 541-7
93. Okubo Y, Bessho K, Fujimura K, et al. The time course study of osteoinduction by bone morphogenetic protein-2 via adenoviral vector. Life Sci 2001 Dec 7; 70 (3): 325-36
94. Franceschi RT, Wang D, Krebsbach PH, et al. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000 Jun 6; 78 (3): 476-86
95. Niyibizi C, Baltzer A, Lattermann C, et al. Potential role for gene therapy in the enhancement of fracture healing. Clin Orthop 1998 Oct; 355 Suppl.: S148-53
96. van Griensven M, Lobenhoffer P, Barke A, et al. Adenoviral gene transfer in a rat fracture model. Lab Anim 2002 Oct; 36 (4): 455-61
97. Baltzer AW, Lattermann C, Whalen JD. et al. Potential role of direct adenoviral gene transfer in enhancing fracture repair. Clin Orthop 2000 Oct; 379 Suppl.: S120-5
98. Fang J, Zhu YY, Smiley E. et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci U S A 1996 Jun; 93 (12): 5753-8
99. Bonadio J, Smiley E, Patil P, et al. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 1999 Jul; 5 (7): 753-9
100. Fibbe WE. Mesenchymal stem cells: a potential source for skeletal repair. Ann Rheum Dis 2002 Nov; 61 Suppl. 2: ii29-31
101. Muschler GF, Nitto H, Boehm CA, et al. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001 Jan; 19 (1): 117-25
102. Caplan AI. The mesengenic process. Clin Plast Surg 1994 Jul; 21 (3): 429-35
103. Bosch P, Musgrave DS, Lee JY, et al. Osteoprogenitor cells within skeletal muscle. J Orthop Res 2000 Nov; 18 (6): 933-44
104. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002 Dec; 13 (12): 4279-95
105. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000 Apr; 109 (1): 235-42
106. Connolly JF, Guse R, Tiedeman J, et al. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop 1991 May; 266: 259-70
107. Connolly J. Guse R, Lippiello L, et al. Development of an osteogenic bone-marrow preparation. J Bone Joint Surg Am 1989 Jun; 71 (5): 684-91
108. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997 Feb; 64 (2): 278-94
109. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001 Jun; 7 (6): 259-64
110. Ishaug-Riley SL, Crane GM, Gurlek A, et al. Ectopic bone formation by marrow stromal osteoblast transplantation using poly(DL-lactic-co-glycolic acid) foams implanted into the rat mesentery. J Biomed Mater Res 1997 Jul; 36 (1): 1-8
111. Solchaga LA, Dennis JE, Goldberg VM, et al. Hyaluronic acid-based polymers as cell carriers for tissue-engineered repair of bone and cartilage. J Orthop Res 1999 Mar; 17 (2): 205-13
112. Boo JS, Yamada Y, Okazaki Y, et al. Tissue-engineered bone using mesenchymal stem cells and a biodegradable scaffold. J Craniofac Surg 2002 Mar; 13 (2): 231-9
113. Burdick JA, Anseth KS. Photoencapsulation of osteoblasts in injectable RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials 2002 Nov; 23 (22): 4315-23
114. Payne RG, Yaszemski MJ, Yasko AW, et al. Development of an injectable, in situ crosslinkable, degradable polymeric carrier for osteogenic cell populations. Part 1: encapsulation of marrow stromal osteoblasts in surface crosslinked gelatin microparticles. Biomaterials 2002 Nov; 23 (22): 4359-71
115. Lieberman JR. Le LQ, Wu L, et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998 May; 16 (3): 330-9
116. Turgeman G, Pittman DD, Muller R, et al. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J Gene Med 2001 May-Jun; 3 (3): 240-51
117. Wright V, Peng H, Usas A, et al. BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Mol Ther 2002 Aug; 6 (2): 169-78
118. Rutherford RB, Moalli M. Franceschi RT, et al. Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng 2002 Jul; 8 (3): 441-52
119. Boden SD, Titus L. Hair G, et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 1998 Dec 1; 23 (23): 2486-92
120. Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 2002 Sep; 110 (6): 751-9
121. Johnson EE, Urist MR, Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein: a preliminary report. Clin Orthop 1988 Nov; 236: 249-57
122. Johnson EE, Urist MR, Finerman GA. Distal metaphyseal tibial non-union: deformity and bone loss treated by open reduction, internal fixation, and human bone morphogenetic protein (hBMP). Clin Orthop 1990 Jan; 250: 234-40
123. Johnson EE, Urist MR, Finerman GA. Resistant nonunions and partial or complete segmental defects of long bones: treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop 1992 Apr; 277: 229-37
124. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002 Aug 15: 27 (16 Suppl. I): S66-85
125. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 2001 Jul; 19 (7): 255-65
126. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988 Dec 16; 242 (4885): 1528-34